secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001171843-25-006973
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing
----------------------------------------------------------------------------

- Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.
- Cash, equivalents & marketable securities $65.7M as of Sept 30, 2025, up from $52.0M at Dec 31, 2024; funding expected into Q4 2026.
- Completed enrollment in soquelitinib atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks); data expected January 2026.
- On track to initiate soquelitinib atopic dermatitis Phase 2 trial in early Q1 2026, targeting ~200 patients.
- Phase 3 registrational trial of soquelitinib in relapsed/refractory PTCL enrolling; final Phase 1/1b results to be presented at ASH December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/0001171843-25-006973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/f8k_110425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer